Key result
Cumulative apoB exposure provides the primary substrate for subclinical plaque, but integrated susceptibility models remain unvalidated.
Why the study?
People with similar current lipid concentrations can have markedly different atherosclerotic burdens, and whether the arterial response to previous apolipoprotein B exposure helps determine when plaque develops is not well established.
Does an integrated metabolic-inflammatory-vascular susceptibility signature explain incident subclinical atherosclerosis plaque onset or progression beyond cumulative apolipoprotein B exposure and conventional risk factors in younger asymptomatic adults?
Does an integrated metabolic-inflammatory-vascular susceptibility signature explain incident subclinical atherosclerosis plaque onset or progression beyond cumulative apolipoprotein B exposure and conventional risk factors in younger asymptomatic adults?
This narrative review proposes a testable metabolic-inflammatory-vascular framework to investigate why individuals with similar cumulative apolipoprotein B exposure develop varying burdens of subclinical atherosclerosis, while emphasizing that early and sustained lipid lowering remains the cornerstone of prevention.
Answers are grounded in this paper and cite their sources.
Apolipoprotein B lowering remains the prevention priority; leaves prospective validation of integrated susceptibility models open.
People with similar current lipid concentrations can have markedly different burdens of atherosclerosis.Much of this difference may reflect previous exposure that a single measurement cannot capture.Whether the arterial response to that exposure also helps determine when plaque develops is less well established.This narrative review examines the evidence for a metabolic-inflammatory-vascular model of disease conversion.Cumulative apolipoprotein B exposure provides the atherogenic substrate; metabolic disturbances, inflammation, and vascular dysfunction may influence its consequences within the arterial wall.Imaging identifies the resulting structural disease.The model is particularly relevant to younger asymptomatic adults, in whom low short-term cardiovascular risk may coexist with early plaque.Its central hypothesis is that a small set of biological characteristics can help explain plaque onset or progression after cumulative exposure and conventional risk factors have been accounted for.Evidence for the integrated metabolic-inflammatory-vascular signature remains indirect; it has not been prospectively validated.Testing this hypothesis requires repeated lipid measurements and prospective imaging, with susceptibility markers assessed before or early in disease.For now, the model offers a way to investigate differences in disease expression, while early and sustained reduction of atherogenic lipoproteins remains the basis of prevention.
No takes yet. Share an insight, caveat, or question.
Mišo Šabović (2026) conducted a review in Subclinical atherosclerosis. Cumulative apolipoprotein B exposure and metabolic-inflammatory-vascular susceptibility was evaluated on Incident imaging-defined subclinical atherosclerosis or plaque progression. Cumulative apolipoprotein B exposure provides the atherogenic substrate for subclinical plaque, while an integrated metabolic-inflammatory-vascular susceptibility model remains prospectively unvalidated.
Synapse has enriched 10 related papers. Consider them for comparative context: